We are live on
!
Find out more
PCH
Polar Capital Holdings Portfolio holdings
AUM
$42.4B
1-Year Est. Return
181.11%
This Fund
S&P 500
This Quarter
Est. Return
-16.7%
1 Year Est. Return
+181.11%
3 Year Est. Return
+584.8%
5 Year Est. Return
+777.19%
10 Year Est. Return
–
AUM
$17B
AUM Growth
-$5.13B
(-23%)
Cap. Flow
-$794M
Cap. Flow
% of AUM
-4.67%
Top 10 Holdings %
Top 10 Hldgs %
43.02%
Holding
494
New
36
Increased
156
Reduced
156
Closed
61
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Salesforce
CRM
|
+$108M |
| 2 |
Visa
V
|
+$102M |
| 3 |
Mercado Libre
MELI
|
+$73M |
| 4 |
Enphase Energy
ENPH
|
+$58.6M |
| 5 |
Snowflake
SNOW
|
+$57.5M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
BHVN
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
|
+$147M |
| 2 |
Y
Alleghany Corp
Y
|
+$137M |
| 3 |
Applied Materials
AMAT
|
+$116M |
| 4 |
Alphabet (Google) Class C
GOOG
|
+$115M |
| 5 |
Alphabet (Google) Class A
GOOGL
|
+$111M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 30.66% |
| 2 | Industrials | 25.1% |
| 3 | Healthcare | 17.44% |
| 4 | Financials | 14.96% |
| 5 | Communication Services | 5.35% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
101
Biogen
BIIB
$32.1B
| $35.7M | 0.21% |
175,000
+50,000
| +40% | +$10.2M |
|
|
GBT
102
DELISTED
Global Blood Therapeutics, Inc.
GBT
| $35M | 0.21% |
1,095,810
| – | – |
|
103
RLI Corp
RLI
$5.63B
| $32.6M | 0.19% |
560,000
+10,000
| +2% | +$573K |
|
104
Workday
WDAY
$46.8B
| $32.6M | 0.19% |
233,522
-41,584
| -15% | -$7.56M |
|
105
Ambarella
AMBA
$2.82B
| $32.3M | 0.19% |
494,095
+51,208
| +12% | +$4.13M |
|
|
BLU
106
DELISTED
BELLUS Health Inc.
BLU
| $32.3M | 0.19% |
3,500,000
+250,000
| +8% | +$2.04M |
|
107
Aflac
AFL
$58.7B
| $31.8M | 0.19% |
575,000
+147,500
| +35% | +$8.71M |
|
108
Legend Biotech
LEGN
$3.6B
| $31.6M | 0.19% |
574,087
+199,217
| +53% | +$8.41M |
|
109
Alnylam Pharmaceuticals
ALNY
$33.5B
| $31.1M | 0.18% |
213,079
-16,754
| -7% | -$2.38M |
|
110
Merit Medical Systems
MMSI
$5.2B
| $30.6M | 0.18% |
563,251
| – | – |
|
111
Arcutis Biotherapeutics
ARQT
$3.05B
| $30M | 0.18% |
1,405,796
-378,209
| -21% | -$7.76M |
|
112
Addus HomeCare
ADUS
$2.19B
| $28.8M | 0.17% |
346,297
| – | – |
|
113
US Foods
USFD
$20.5B
| $27.9M | 0.16% |
908,863
+25,453
| +3% | +$861K |
|
114
Bank of America
BAC
$416B
| $27.5M | 0.16% |
884,050
+203,560
| +30% | +$7.33M |
|
115
Linde
LIN
$214B
| $27.3M | 0.16% |
79,240
+3,634
| +5% | +$1.14M |
|
116
Shopify
SHOP
$172B
| $27.2M | 0.16% |
870,860
-411,710
| -32% | -$17.6M |
|
117
Zentalis Pharmaceuticals
ZNTL
$331M
| $26.7M | 0.16% |
950,151
+580,822
| +157% | +$15.4M |
|
118
United Rentals
URI
$61.6B
| $26.3M | 0.15% |
108,099
+3,027
| +3% | +$891K |
|
|
NSTG
119
DELISTED
NanoString Technologies, Inc.
NSTG
| $25.7M | 0.15% |
2,026,169
+408,436
| +25% | +$7.61M |
|
120
Alcon
ALC
$32.7B
| $25.3M | 0.15% |
362,824
-117,118
| -24% | -$8.54M |
|
121
Analog Devices
ADI
$175B
| $25.1M | 0.15% |
171,963
-6,009
| -3% | -$946K |
|
122
JPMorgan Chase
JPM
$931B
| $24.3M | 0.14% |
215,718
-42,767
| -17% | -$5.3M |
|
123
Service Corp International
SCI
$11.2B
| $24.2M | 0.14% |
350,419
| – | – |
|
124
Elevance Health
ELV
$90.8B
| $24.1M | 0.14% |
49,844
-16,218
| -25% | -$8.02M |
|
125
Toronto Dominion Bank
TD
$198B
| $23.7M | 0.14% |
314,565
-1,143
| -0.4% | -$83K |
|
Similar funds
GAM
SAM
Polar Capital Holdings's Q2 2022 Portfolio in Review
As of Q2 2022, Polar Capital Holdings held 494 positions worth $17B, down 23% from $22.2B the previous quarter. Its ten largest holdings account for 43% of the portfolio.
Polar Capital Holdings withdrew a net $794M in Q2 2022, closing 61 positions and reducing 156 holdings. Its most notable exit was Biohaven Pharmaceutical Holding Company Ltd., an estimated $147M position sold in full.
By sector, the portfolio is most concentrated in Technology at 31% of assets, down from 33% a quarter earlier, followed by Industrials and Healthcare.
Against the trend, Polar Capital Holdings opened a new position in Sanofi worth $36.3M.
- Polar Capital Holdings's largest Q2 2022 buy was Sanofi: 725,000 shares worth $36.3M.
- Polar Capital Holdings added most to Salesforce in Q2 2022, an estimated $108M increase.
- Polar Capital Holdings's biggest Q2 2022 reduction was Applied Materials, cutting an estimated $116M.
- Polar Capital Holdings fully exited Biohaven Pharmaceutical Holding Company Ltd. in Q2 2022, selling an estimated $147M.
- Polar Capital Holdings's ten largest holdings make up 43% of its $17B portfolio in Q2 2022.
- Polar Capital Holdings opened 36 new positions and closed 61 in Q2 2022.
- Polar Capital Holdings's portfolio value fell 23% quarter-over-quarter to $17B.
Based on Polar Capital Holdings's 13F filing for Q2 2022, filed 15 Aug 2022.